Migraine Sufferers Demand Funding for Lifesaving Treatments

Chronic migraine sufferers in New Zealand are advocating for government funding of effective treatments, citing debilitating pain that has sidelined them from the workforce. As the demand for accessible therapies grows, personal stories reveal the profound impact these conditions have on individuals and the economy.

Chronic Pain and Economic Impact

For many, a headache is a minor annoyance easily remedied by over-the-counter painkillers. For others, like Lisa Hindmarsh, migraines can lead to debilitating episodes that drastically alter daily life. Hindmarsh, who experienced her first migraine just two years ago, has faced intense pain, often bedridden for three weeks each month. The condition forced her out of her job as a beauty therapist and required her parents to take care of her children while her husband worked tirelessly to make ends meet.

“It’s really, really hard for people to understand the true extent of this chronic pain,” Hindmarsh explained to the Sunday Star-Times. “It feels like a sharp, stabbing pain around my eye, accompanied by nausea and visual disturbances.”

Despite trying various medications, including non-migraine-specific treatments like nortriptyline and propranolol, her struggle continued. These drugs often resulted in side effects that left her feeling groggy and unable to function.

Eventually, she discovered anti-CGRP medications, specifically designed for migraine treatment. These include Aquipta and Aimovig, which have been hailed by the Migraine Foundation as revolutionary. However, access to these medications is hindered by their high cost and lack of funding. Aquipta, for example, can cost around $350 per month, a financial burden for many who are unable to work due to their condition.

Calls for Action and Funding

Hindmarsh’s situation reflects a broader issue faced by many chronic migraine sufferers in New Zealand. Fellow advocate Kat Soper has experienced similar challenges since suffering a head injury in 2020 that triggered debilitating headaches. Previously a successful business coach, Soper found herself unable to work for extended periods, ultimately transitioning to part-time employment.

Her treatment journey mirrors Hindmarsh’s, as she also cycled through various funded medications before finding relief with Emgality, another anti-CGRP medication. The cost of this treatment, approximately $300 per month after an initial loading dose, continues to strain her finances, especially as her part-time role as a teacher aide does not provide a consistent income.

Soper believes that funding such medications could enhance workforce productivity. “I went from being fully functional to barely managing part-time hours,” she noted, underscoring the economic implications of untreated migraines.

The pressure for funding has reached the ears of policymakers. David Seymour, New Zealand’s Associate Health Minister, has expressed his intention to advocate for increased funding for the drug-buying agency, Pharmac. However, he acknowledged that final decisions regarding which drugs to fund must be based on data and clinical evidence, rather than political considerations.

Pharmac’s manager of pharmaceutical funding, Claire Pouwels, confirmed that multiple applications for funding anti-CGRP medications are under review. “We have completed our assessment and determined that they are treatments we would like to fund when budget allows,” Pouwels stated. Yet, she reiterated that there is no clear timeline for when this might occur.

According to the Migraine Foundation, over half of those who attempt standard migraine preventive medications discontinue them due to ineffectiveness or side effects. This statistic highlights the urgent need for accessible and effective treatments.

Dr. Ray Bose, a neurologist in Auckland, emphasized the unmet need for better access to migraine treatments, noting that approximately 10% of the population suffers from migraines. The lack of funding for effective medications presents a significant barrier to treatment.

Data from Alberta, Canada, suggests that healthcare costs for individuals with chronic migraines are roughly 1.5 times greater than for the general population, translating to an additional annual burden of CAD$5059 (approximately NZD$6276). Given that lost productivity due to migraines can exceed healthcare costs, the economic implications for New Zealand are substantial, potentially exceeding $1 billion annually.

Both Hindmarsh and Soper believe that New Zealand is lagging behind other countries in supporting those with chronic migraines. While CGRP treatments are funded in many OECD nations, they remain out of reach for many in New Zealand due to high costs and lack of coverage.

The experiences shared by these advocates reveal the emotional and financial toll of living with chronic migraines. Hindmarsh poignantly described the heartbreak of missing significant family events due to her condition, emphasizing the need for effective treatments at reasonable costs.

As discussions continue around funding and accessibility, the voices of those affected remain crucial in driving change for better healthcare solutions. Their stories serve as a reminder of the urgency for action in addressing the challenges faced by millions living with chronic migraine pain.